WallStreetZenWallStreetZen

NASDAQ: SLNO
Soleno Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SLNO

Based on 4 analysts offering 12 month price targets for Soleno Therapeutics Inc

Min Forecast
$75.00+89.01%
Avg Forecast
$92.50+133.11%
Max Forecast
$110.00+177.22%

Should I buy or sell SLNO stock?

Based on 4 analysts offering ratings for Soleno Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SLNO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SLNO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their SLNO stock forecasts and price targets.

SLNO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-04
lockedlocked$00.00+00.00%2026-02-27
lockedlocked$00.00+00.00%2026-02-26
lockedlocked$00.00+00.00%2025-11-18

1 of 1

Forecast return on equity

Is SLNO forecast to generate an efficient return?

Company
119.61%
Industry
43.15%
Market
165.49%
SLNO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SLNO forecast to generate an efficient return on assets?

Company
95.49%
Industry
11.03%
SLNO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SLNO earnings per share forecast

What is SLNO's earnings per share in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$4.30+974.15%
Avg 2 year Forecast
$6.95+1,637.83%
Avg 3 year Forecast
$10.43+2,507.2%
SLNO's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

SLNO revenue forecast

What is SLNO's revenue in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
$486.4M+155.44%
Avg 2 year Forecast
$768.4M+303.56%
Avg 3 year Forecast
$1.1B+464.59%
SLNO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SLNO earnings growth forecast

How is SLNO forecast to perform vs Biotechnology companies and vs the US market?

Company
324.84%
Industry
15.72%
Market
76.34%
SLNO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
SLNO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
SLNO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

SLNO revenue growth forecast

How is SLNO forecast to perform vs Biotechnology companies and vs the US market?

Company
101.94%
Industry
51.04%
Market
15.33%
SLNO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SLNO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SLNO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SLNO$39.68$92.50+133.11%Strong Buy
RARE$21.25$56.77+167.15%Strong Buy
MESO$15.85N/AN/A
STOK$35.48$37.00+4.28%Strong Buy
AAPG$23.14$48.50+109.59%Strong Buy
View Top Biotech Stocks

Soleno Therapeutics Stock Forecast FAQ

Is Soleno Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: SLNO) stock is to Strong Buy SLNO stock.

Out of 4 analysts, 2 (50%) are recommending SLNO as a Strong Buy, 2 (50%) are recommending SLNO as a Buy, 0 (0%) are recommending SLNO as a Hold, 0 (0%) are recommending SLNO as a Sell, and 0 (0%) are recommending SLNO as a Strong Sell.

If you're new to stock investing, here's how to buy Soleno Therapeutics stock.

What is SLNO's earnings growth forecast for 2026-2028?

(NASDAQ: SLNO) Soleno Therapeutics's forecast annual earnings growth rate of 324.84% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.72%, and it is also forecast to beat the US market's average forecast earnings growth rate of 76.34%.

Soleno Therapeutics's earnings in 2026 is $20,475,000.On average, 15 Wall Street analysts forecast SLNO's earnings for 2026 to be $221,809,328, with the lowest SLNO earnings forecast at $147,222,418, and the highest SLNO earnings forecast at $300,841,098. On average, 12 Wall Street analysts forecast SLNO's earnings for 2027 to be $358,856,580, with the lowest SLNO earnings forecast at $269,148,888, and the highest SLNO earnings forecast at $537,719,584.

In 2028, SLNO is forecast to generate $538,380,376 in earnings, with the lowest earnings forecast at $452,291,553 and the highest earnings forecast at $771,345,734.

What is SLNO's revenue growth forecast for 2026-2028?

(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of 101.94% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 51.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.33%.

Soleno Therapeutics's revenue in 2026 is $190,405,000.On average, 13 Wall Street analysts forecast SLNO's revenue for 2026 to be $25,108,551,646, with the lowest SLNO revenue forecast at $21,937,781,981, and the highest SLNO revenue forecast at $30,517,754,602. On average, 11 Wall Street analysts forecast SLNO's revenue for 2027 to be $39,668,176,666, with the lowest SLNO revenue forecast at $32,432,503,004, and the highest SLNO revenue forecast at $47,700,930,816.

In 2028, SLNO is forecast to generate $55,496,212,800 in revenue, with the lowest revenue forecast at $47,010,196,558 and the highest revenue forecast at $66,130,835,904.

What is SLNO's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: SLNO) forecast ROA is 95.49%, which is higher than the forecast US Biotechnology industry average of 11.03%.

What is SLNO's Price Target?

According to 4 Wall Street analysts that have issued a 1 year SLNO price target, the average SLNO price target is $92.50, with the highest SLNO stock price forecast at $110.00 and the lowest SLNO stock price forecast at $75.00.

On average, Wall Street analysts predict that Soleno Therapeutics's share price could reach $92.50 by Mar 4, 2027. The average Soleno Therapeutics stock price prediction forecasts a potential upside of 133.11% from the current SLNO share price of $39.68.

What is SLNO's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SLNO) Soleno Therapeutics's current Earnings Per Share (EPS) is $0.40. On average, analysts forecast that SLNO's EPS will be $4.30 for 2026, with the lowest EPS forecast at $2.85, and the highest EPS forecast at $5.83. On average, analysts forecast that SLNO's EPS will be $6.95 for 2027, with the lowest EPS forecast at $5.21, and the highest EPS forecast at $10.42. In 2028, SLNO's EPS is forecast to hit $10.43 (min: $8.76, max: $14.94).

What is SLNO's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: SLNO) forecast ROE is 119.61%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.